Abstract Body

To reach the goal of end-Tuberculosis strategy, new biomarkers are needed to identify active tuberculosis (TB). Currently, only QuantiFERON® TB assay (QTF) is used in peripheral blood for screening tuberculosis infection. However, this method cannot distinguish active from latent TB infection (LTBI). Recent studies show a transcriptional increase of several genes, including CD64, which code for a high affinity Fc receptor I involved in inflammatory reactions. In addition, Neutrophils (NE) and Monocytes (MO) exert bactericidal responses by producing inflammatory proteins caused by infection with M. Tuberculosis (MBT). The purpose of this study was to quantify CD64 expression on the surface of NE and MO as a predictive biomarker of progression from LTBI to active TB in QuantiFERON® (QTF) positive or indeterminate patients

Patients were enrolled with positive and indeterminate QTF. Non-systemic infections were documented. Flow cytometric quantitative expression of CD64 was evaluated from peripheral blood samples and expressed in ABC (Antibody Binding Capacity) units, with NE normal range <1000 ABC and MO normal range 15000-20000 ABC. MTB cultures from respiratory specimens were also performed.

Of the 45 positive QTF cases, 25 MTB cultures were positive and 16 were negative. The positive QTF with negative MTB cultures were considered LTBI. The median of NE CD64 ABC and MO CD64 ABC was significantly higher (p<0.001) in MTB positive cultures (NE 3593 ABC; MO 38757 ABC) than in MTB negative cultures (NE 724 ABC; MO 17151 ABC) (Fig. a). The NE CD64 and MO CD64 AUC-ROC values were 0.948 (95% CI 0.838-0.992) and 0.989 (0.901-1.000), respectively (Fig. b). By establishing the NE CD64 value of >2400 ABC or the MO CD64 value of >25800, the sensitivity increased to 95.5% (82.2-99.9) with 100% specificity and 100% Positive Predictive Values (PPVs) (Fig. c). Of the 6 indeterminate QTF enrolled, the 4 with MTB positive cultures showed NE CD64 >2400 ABC or MO CD64 value >25800 ABC and the 2 with MTB negative cultures showed NE CD64 <1000 ABC or MO CD64 <23000 ABC.

The quantification of NE and MO CD64 expression is a powerful diagnostic tool in discriminating between active TB and LTBI and may be used as predictive biomarker of active TB in patients with a positive QTF test. Providing a fast diagnostic solution, this may address the limitation of current tuberculosis diagnostics. Further studies with a larger patient cohort are needed to validate our preliminary data.